The Weekend Round up for May 2019 @ The Hemp Club.co.uk
1. There’s too much junk in the CBD market. 2. Consumers have no way of knowing what’s legitimate. 3. Many people still have no clue what CBD is. 4. The FDA has serious concerns about side effects. 5. Anecdotal evidence doesn’t play well at the FDA.
Europe’s Fast-Growing Marijuana Market
The Canadian marijuana producer’s recent small deal could be a bigger deal over the long run.
“The cash cost to produce per gram came down significantly from $1.92 to $1.42. So, that’s down 26%. We knew this was coming. We knew that would result from the scale, efficiency, and technology of Aurora Sky, but it’s very gratifying to see.”
The pharmacy chain has to walk a fine line, as the FDA is keeping close tabs on its moves.
New division will focus on building a European ecosystem to improve patient access to medical cannabis
Astral Health, an arm of ECH Group, which was created last year to increase awareness of and pateint access to medical cannabis, has teamed up with London-based drugs wholesaler Miller & Miller. The joint venture will source and distribute high-quality medical-grade cannabis from all over the world to patients in the UK and Europe.
England rugby player launches CBD business ahead of speaking at Cannabis Europa.
Many thanks to the Daily Telegraph, Prohibition Partners, Motley Fool, Leafly and PR Newswire: please follow links in each article header for full story